Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1089/omi.2020.0071 http://scihub22266oqcxt.onion/10.1089/omi.2020.0071 32757981!ä!32757981 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32757981&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       OMICS 2020 ; 24 (10): 568-580 Nephropedia Template TP {{tp|p=32757981|t=2020. In silico Potential of Approved Antimalarial Drugs for Repurposing Against COVID-19 |pdf=|usr=}}{{32757981}} gab.com Text In silico Potential of Approved Antimalarial Drugs for Repurposing Against COVID-19 JO: OMICS http://www.kidney.de/pget.php?&tw=1&pmid=32757981 #FOAvip Although the coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is wreaking havoc and resulting in mortality and morbidity across the planet, novel treatments are urgently needed. Drug repurposing offers an innovative approach in this context. We report here new findings on the in silico potential of several antimalarial drugs for repurposing against COVID-19. We conducted analyses by docking the compounds against two SARS-CoV-2-specific targets: (1) the receptor binding domain spike protein and (2) the main protease of the virus (M(Pro)) using the Schrodinger software. Importantly, the docking analysis revealed that doxycycline (DOX) showed the most effective binding to the spike protein of SARS-CoV-2, whereas halofantrine and mefloquine bound effectively with the main protease among the antimalarial drugs evaluated in the present study. The in silico approach reported here suggested that DOX could potentially be a good candidate for repurposing for COVID-19. In contrast, to decipher the actual potential of DOX and halofantrine against COVID-19, further in vitro and in vivo studies are called for. Drug repurposing warrants consideration as a viable research and innovation avenue as planetary health efforts to fight the COVID-19 continue. Twit Text FOAVip In silico Potential of Approved Antimalarial Drugs for Repurposing Against COVID-19 ????OMICS http://www.kidney.de/pget.php?&tw=1&pmid=32757981 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32757981 #FOAvip English Wikipedia <ref>{{Cite pmid|32757981}}</ref> In silico Potential of Approved Antimalarial Drugs for Repurposing Against COVID-19 #MMPMID32757981 Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK OMICS 2020[Oct]; 24 (10): 568-580 PMID32757981show ga Although the coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is wreaking havoc and resulting in mortality and morbidity across the planet, novel treatments are urgently needed. Drug repurposing offers an innovative approach in this context. We report here new findings on the in silico potential of several antimalarial drugs for repurposing against COVID-19. We conducted analyses by docking the compounds against two SARS-CoV-2-specific targets: (1) the receptor binding domain spike protein and (2) the main protease of the virus (M(Pro)) using the Schrodinger software. Importantly, the docking analysis revealed that doxycycline (DOX) showed the most effective binding to the spike protein of SARS-CoV-2, whereas halofantrine and mefloquine bound effectively with the main protease among the antimalarial drugs evaluated in the present study. The in silico approach reported here suggested that DOX could potentially be a good candidate for repurposing for COVID-19. In contrast, to decipher the actual potential of DOX and halofantrine against COVID-19, further in vitro and in vivo studies are called for. Drug repurposing warrants consideration as a viable research and innovation avenue as planetary health efforts to fight the COVID-19 continue. |Antimalarials/chemistry/*pharmacology[MESH] |Antiviral Agents/chemistry/*pharmacology[MESH] |Betacoronavirus/chemistry/*drug effects[MESH] |Binding Sites[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Computer Simulation[MESH] |Coronavirus 3C Proteases[MESH] |Coronavirus Infections/*drug therapy/epidemiology/virology[MESH] |Cysteine Endopeptidases/chemistry/drug effects[MESH] |Doxycycline/chemistry/pharmacology[MESH] |Drug Evaluation, Preclinical[MESH] |Drug Repositioning/*methods[MESH] |Humans[MESH] |Molecular Docking Simulation[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/epidemiology/virology[MESH] |SARS-CoV-2[MESH] |Spike Glycoprotein, Coronavirus/chemistry/drug effects[MESH]In silico Potential of Approved Antimalarial Drugs for Repurposing Aga(epmc).pdf DeepDyve Pubget Overpricing